ReviewJournal of patient-reported outcomes2026
Patient-reported outcomes in chronic GVHD: instruments, clinical utility, and survivorship integration.
Review in Journal of patient-reported outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic graft-versus-host disease (cGVHD) is a leading driver of long-term morbidity after allogeneic transplantation. This review synthesizes evidence on patient-reported outcomes (PROs) across organ systems and survivorship domains, appraises psychometrics and minimal clinically important differences (MCIDs), and translates measures into routine care. Validated tools-including the Lee Symptom Scale (LSS), FACT-BMT, SF-36, PROMIS, and pediatric instruments-capture symptom burden and function beyond clinician ratings, and studies have demonstrated associations of some measures with survival, failure-free survival, and non-relapse mortality. Concordance between provider-rated and PRO-defined responses is limited, while PRO changes often track clinically meaningful improvement. We propose an implementation framework and two practical tables mapping measures to organ involvement and use-cases. Key barriers include workflow integration, patient burden, and cross-cultural adaptation-gaps that are pronounced in Chinese cohorts. Embedding PROs in trials and survivorship models can sharpen risk stratification, inform shared decisions, and improve patient-centered outcomes in cGVHD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.